How is Liraglutide (Saxenda / Victoza) administered?
This describes how Liraglutide (Saxenda / Victoza) is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once daily schedule, generally over open-ended, titrate over months. Specific dosing is individual and beyond general information, and human evidence for Liraglutide (Saxenda / Victoza) is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once daily
- Cycle length: Open-ended, titrate over months
- Half-life: ~13 hours
References
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity) — Pi-Sunyer X et al., NEJM, 2015
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) — Marso SP et al., New England Journal of Medicine, 2016
- Victoza (liraglutide) — Drugs@FDA approval record (ApplNo 022341) — FDA, Drugs@FDA
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Liraglutide (Saxenda / Victoza)
Full Liraglutide (Saxenda / Victoza) breakdownLiraglutide (Saxenda / Victoza) what it's used forLiraglutide (Saxenda / Victoza) side effectsLiraglutide (Saxenda / Victoza) mistakes to avoidLiraglutide (Saxenda / Victoza) who should avoid itLiraglutide (Saxenda / Victoza) half-lifeLiraglutide (Saxenda / Victoza) how long to workLiraglutide (Saxenda / Victoza) legal statusLiraglutide (Saxenda / Victoza) how it worksAsk the AI Coach
Last updated 2026-06-15.